CureDuchenne
Po-Ting Liu has an extensive background in virology and gene therapy, with experience working at various prestigious institutions such as Harvard Medical School and Takeda. Currently serving as a Venture Associate at CureDuchenne, Po-Ting Liu previously held roles such as Senior Scientist at a Stealth Startup and Research Scientist at Takeda. With a Ph.D. in Virology from Harvard Medical School, Po-Ting Liu's expertise includes optimizing gene therapy vectors and developing novel regulatory elements for both viral and non-viral gene therapy. Prior research includes projects on HIV prevention and the identification of viral reservoirs in rhesus monkeys.
This person is not in any offices
CureDuchenne
CureDuchenne is the global leader in Duchenne research, patient care and innovation. We are committed to improving the lives of those affected by Duchenne through accelerating research, improving care and empowering the community. cureduchenne.org Founded by Paul and Debra Miller in 2003, after their son was diagnosed with the disease, CureDuchenne combines fundraising and venture philanthropy leveraging donor dollars to maximize support for promising research into effective treatments for those suffering from Duchenne. With transparency as a core value, investment proceeds are redeployed to support research and other mission critical programs to find a cure.